openwiki-wiki/commitments.md

---
type: "Reference"
title: "Commitments"
description: "Active work tasks, follow-ups, approvals, and scheduled items extracted from sources (web-search, git-repo, literature flywheel-sync, etc.). Personal errands live in /personal-logistics.md instead."
tags: [commitments, work, follow-ups, distributors-2026-08-07-refresh, dong-huiqun-ji-nan-chengquan-link, liang-2026-celvivo-clinostar-positioning, guo-2026-organoid-irb-checklist-rollout]
---

# Commitments

Concrete work tasks, follow-ups, approvals, and scheduled items extracted from Gmail, Notion, Slack, direct mentions, and other work-relevant sources. Personal errands and life admin live in `/personal-logistics.md` instead.

## Active

### china-cde-cell-gene-therapy-rules-2026: verify CDE classification scope for Chinese pharma / CDMO conversations
- Owner: me
- Source: web-search — cisema.com 2026-07-24 (China CDE Defines Classification Rules for Cell & Gene Therapy Drugs)
- Due: unscheduled
- Status: open
- Notes: Single credible regulatory-trade source. Pull the NMPA/CDE-direct release before the next vendor sync; check whether any active CellShot-TriArm or ClinoReactor-class deals depend on the new classification scope.

### celvivo-clinoreactor-thewell-bioscience-xeno-free: verify TheWell Bioscience co-marketing signal on next CelVivo check
- Owner: me
- Source: web-search — thewellbio.com 2026-07-21 / 2026-07-23 / 2026-07-25 (Xeno-Free Cell Culture Media, Stem Cell Culture Product Guide, Apical-Out Organoids white paper — all explicitly name "CelVivo ClinoReactor™")
- Due: unscheduled
- Status: open
- Notes: First vendor-anchored CelVivo ClinoReactor signal in any Tavily pull (prior pulls returned only MO:BOT / generic organoid). TheWell Bioscience is a hydrogel-media partner; their workflow pages position ClinoReactor as the scale-up vessel for apical-out organoids + hMSC expansion. Confirm with CelVivo whether this is a sanctioned co-marketing arrangement and whether it maps to any active Chinese pharma / CDMO deal.

### china-order-no-818-clinical-translation: verify Order No. 818 (effective 2026-05-01) scope for Chinese pharma / CDMO conversations
- Owner: me
- Source: web-search — BetaLife LinkedIn 2026-07 (top score 0.779; explicitly cites "Order No. 818, effective May 1, 2026" with accelerated clinical-translation pathway); Tavily answer text corroborates; Roots Analysis re-mentions broader China cell-therapy regulatory pattern
- Due: unscheduled
- Status: open
- Notes: Single primary source (BetaLife SG LinkedIn) but the regulation itself is a published policy text — Order No. 818 creates an accelerated clinical-translation pathway at qualified hospitals for cell therapy and 3D bioprinting after demonstrating safety and preliminary efficacy. This is **the clinical-translation counterpart** to the existing `china-cde-cell-gene-therapy-rules-2026` item (which is about classification / CMC planning). Both items matter: classification scope drives dossier content vendors need to assemble; the clinical-translation pathway drives which hospitals can host first-in-human studies. Pull the NMPA / State Council Order No. 818 direct text before the next vendor sync; check whether any active CellShot-TriArm or ClinoReactor-class deal depends on whether the buyer hospital qualifies as a "qualified hospital" under the regulation.

### cellink-bio-x-gen3-customer-evidence: verify Cellink BIO X Gen 3 / BIO X6 customer pipeline on next Cellink check
- Owner: me
- Source: web-search — Nuclear Mechano-Oncology LinkedIn 2026-07 (score 0.601; "our new BIO X Gen 3 bioprinter has now been installed … first hands-on training session"); CELLINK official LinkedIn 2026-07-28 (score 0.287; BIO X6 at University of Miami 3D Bioprinting Facility); third-party market report LinkedIn 2026-07-28 (score 0.659; Cellink revenue uptick following strategic acquisitions); appellaser.ro practical selection guide 2026-07-24 (score 0.303; BIO X Gen 3 general-purpose positioning)
- Due: unscheduled
- Status: open
- Notes: First vendor-anchored Cellink signal in any Tavily pull after 5 prior pulls of zero Cellink product mentions. Four distinct sources: customer install LinkedIn (Eastern Europe), vendor LinkedIn (CELLINK U. Miami), market report, independent selection guide. Verify with Cellink whether the BIO X Gen 3 / BIO X6 nomenclature is current product naming or if one is being deprecated; whether any of the named customer accounts (Nuclear Mechano-Oncology; U. Miami 3D Bioprinting Facility) maps to active Chinese pharma R&D / CDMO opportunities. Companion to the existing `celvivo-clinoreactor-thewell-bioscience-xeno-free` item.

### china-cgt-2026-july-developments: monitor gene-editing trial death fallout + Merck–Bio-Techne / CARsgen satri-cel context for Chinese pharma / CDMO positioning
- Owner: me
- Source: web-search — Straits Times 2026-07-24 (score 0.313; patient death in China gene-editing trial draws fire); LiveScience 2026-07-24 (score 0.145; 6-year-old girl, investigation into gene-therapy regulations); SCMP 2026-07-29 (score 0.203; "Fear of policy backlash" — same-day coverage with this Tavily pull); Roots Analysis 2026-07-24 (score 0.669; Merck–Bio-Techne $11.3B acquisition June 2026 + CARsgen satri-cel CAR-T approval for stomach cancer June 2026); BioSpace 2026-07-27 (score 0.535; Summit/Merck China-first regulatory navigation)
- Due: unscheduled
- Status: open
- Notes: Material new development in the China regulatory lane — sits **on top of** the existing `china-cde-cell-gene-therapy-rules-2026` and `china-order-no-818-clinical-translation` items, not replacing them. Two positive signals (Merck–Bio-Techne acquisition; CARsgen satri-cel solid-tumor CAR-T approval) show the China CGT manufacturing environment is consolidating around advanced therapeutics. One negative signal (gene-editing trial death + published regulatory backlash) could foreshadow stricter CDE / NMPA / hospital-level oversight and tighter qualification criteria for "qualified hospitals" under Order No. 818. Together these affect: (a) qualification timelines for the CellShot-TriArm and ClinoReactor-class deals Robin has in flight, (b) which "qualified hospitals" remain eligible to host first-in-human studies, (c) whether CelVivo / 3Brain / Cellink vendor positioning for Chinese pharma R&D / CDMO accounts needs to change tone (e.g. emphasize safety documentation, IRB-grade workflows). Pull NMPA / hospital-IRB statements on the gene-editing trial case before next Chinese customer conversation.

### 3brain-coreplate-2026-conference-positioning: verify current CorePlate campaign and retrieve application material on next 3Brain check
- Owner: me
- Source: web-search — 3Brain official website plus 3Brain organization material captured through LinkedIn in Tavily pull 7 (2026-07-30); the dated result is 2026-07-25 and names ISSCR 2026 booth 412, while the company page also names ELRIG Drug Discovery booth 4. Tavily pull 11 (2026-08-03) adds a 3Brain LinkedIn post dated 2026-07-29 ("3Brain contributes to Utrecht Summer School course on Human Brain Models", score 0.808) — the **first Tavily pull where the 3Brain answer text is not mis-attribution** — and the 3Brain AG company LinkedIn page (score 0.839)
- Due: unscheduled
- Status: open
- Notes: First credible direct 3Brain evidence after five Tavily pulls dominated by an unrelated EEG-paper mis-attribution. Vendor material positions CorePlate-enabled HD-MEA for high-resolution, scalable functional readouts from iPSC neuronal/cardiac models, brain organoids, assembloids, and 3D spheroids. Pull 11 extends the vendor-channel strand to the academic / training segment (Utrecht Summer School "Human Brain Models" course) on top of the ISSCR / ELRIG conference-booth strand from pull 7. Confirm which conference posts are current, obtain the named posters / application notes / Utrecht course module, and map them to Chinese neural-organoid and pharma-screening prospects. This pull does not establish CorePlate 1W/6W load force or Sample Holder Set details.

### celvivo-clinostar-2-nams-demo-2026: verify product naming and campaign provenance on next CelVivo check
- Owner: me
- Source: web-search — Instagram snippets surfaced in Tavily pull 7 (2026-07-30): ClinoStar webinar copy (`DbaUZjIjMgK`), NexUs Locus on-site demo copy dated 2026-07-24 (`DbKYC4NBtrN`), and ClinoStar 2 NAMs positioning (`DbSl7nkoFjK`). Tavily pull 11 (2026-08-03) adds an **independent confirmation** from an Indian distributor event page (labindia-analytical.com News & Events, score 0.696) that CelVivo is exhibiting at Thailand Lab 2026 (Bangkok, 2026-09-02 → 2026-09-04) and that `ClinoStar 2` is current product naming with oxygen regulation as a distinguishing feature
- Due: unscheduled
- Status: open
- Notes: Watchlist lead, not a confirmed launch or customer win. Verify that the posts come from CelVivo or an authorized distributor, whether `ClinoStar 2` is current official product naming, and whether the NexUs Locus live demo produced reusable data or contacts. Pull 11's labindia-analytical.com result is the **first non-Instagram, named-event confirmation** of ClinoStar 2 + Thailand Lab 2026; treat it as independent corroboration, not vendor-direct. The result set does not support Tavily's “installed base” language; one malformed duplicate URL was discarded.

### cellink-volumetric-lumen-x-release: verify CELLINK × Volumetric new Lumen X release on next Cellink check
- Owner: me
- Source: web-search — Tavily pull 11 (2026-08-03) top hit on `Cellink BIO X bioprinter 2026`: 3DPrint.com 2026-07-28 (score 0.819) "CELLINK and Volumetric Release New Lumen X for Lumen X Bioprinting". Tavily answer text corroborates and adds BioMET '26 Vellore India (2026-08-05 → 2026-08-07) showcase detail. Companion evidence: Cellink LinkedIn 2026-07-29 (score 0.762) BioMET '26 exhibiting post; CELLINK Facebook 2026-07-28 (score 0.632) second-conference post
- Due: unscheduled
- Status: open
- Notes: **First credible direct Cellink product / partnership release evidence on the Robin portfolio** after 10 prior Tavily pulls dominated by mis-attribution or BIO X Gen 3 / BIO X6 customer evidence (see existing `cellink-bio-x-gen3-customer-evidence`). Lumen X is in Robin's portfolio table ("Cellink — BIO X / BIONOVA X / Lumen X"). Verify with Cellink: (a) what is the relationship between CELLINK and Volumetric — co-marketing, OEM, distribution, or full acquisition; (b) is "New Lumen X" a distinct SKU from the original Lumen X (volumetric DLP) or a refresh; (c) does BioMET '26 Vellore presence map to any active Chinese pharma R&D / CDMO / biotech opportunities (likely India-channel rather than China-channel — adjacent to Robin's region); (d) does the existing `cellink-bio-x-gen3-customer-evidence` commitment's BIO X6 at U. Miami installation narrative change in light of this release.

### itx-24h-host-build-2026-q3: finish assembly + Ubuntu + Hermes install on Robin's 24h host (paused since hardware is 10/11 arrived)
- Owner: me
- Source: git-repo — `03-Resources/ITX-24h-Host/ITX_24h_Host_v18_Config_2026-07-31.md` (Obsidian vault, untracked as of fetch 2026-07-31T18:08:12Z)
- Due: unscheduled (waiting for the last #8 / #9 cable parts on hand; once on hand, finish the assembly + software stack)
- Status: open
- Notes: Personal-infra work item (workflow-tooling priority LOW), not vendor-anchored — logged here because it is source-anchored to Robin's actual vault work per the brief's commitments.md rule ("only real Robin commitments"). Plan: mATX + i5-12400 + DDR4-2666 32G + 板载 Realtek 1Gb + Intel PRO/1000 GT (¥2,985.82, 10/11 parts on hand). Two 网卡 VLAN: 192.168.31.100 → 主力机 Win 11 SSH, 10.10.10.254 → 主力 NAS RAGFlow. Post-assembly steps: Ubuntu Server 22.04 LTS install, partition `/` (GM7 512G) + `/data` (mSATA 512G), Docker, dual-NIC 静态 IP, 主力机 SSH key 免密, NAS RAGFlow API 接入, 安装 Hermes Agent, 24h 跑功耗 soak test. The host has no vendor-product overlap; not promoted to `/themes.md` row because that index is reserved for recurring workflow signals.

### liu-2026-hd-mea-roadmap-implication: verify with 3Brain whether the Liu 2026 shape-conformal framework is on their product roadmap
- Owner: me
- Source: literature flywheel-sync 2026-08-08 — Liu N et al. (2026) Nature Biomedical Engineering, DOI 10.1038/s41551-026-01620-y, Wiki.js Id 1692, NocoDB row 1 in **new table `Robin_Picked_Papers`** (created 2026-08-08, table_id `mbjo0wb56qv1qly`), SeaFile PDF https://fb.biokingdom.top/f/6da50240729e41bdb369/?dl=1. Deep-read synthesis at [`/sources/literature-liu-2026-nbme-shape-conformal-organoid-deepread.md`](/sources/literature-liu-2026-nbme-shape-conformal-organoid-deepread.md)
- Due: unscheduled
- Status: open
- Notes: **Highest product-relevance cluster of today's flywheel-sync**: HD-MEA rating 5 (3000-8000 channels vs current 3Brain Accura-3D 4096; >90% surface coverage vs 5-15% bottom-only), 3D bioprinting microlattice rating 5 (Cellink BIONOVA X / Lumen X cannot directly print at this resolution today but the field direction is clear), patient-derived organoid drug screening rating 5 (first long-term high-throughput electrophysiology drug screening platform — weeks-long stable recording + epilepsy + AD disease modeling). Robin should sell 3Brain's current 4096-electrode Accura-3D as the existing best-in-class AND track whether 3Brain has a flexible-electronics / shape-conformal framework on their roadmap. Companion question on `/open-questions.md`: `liu-2026-rogers-lab-vs-3brain-relationship` (is there any partnership / licensing / competitive pressure between Rogers Lab and 3Brain?). Companion commitment to verify with Cellink: `liu-2026-cellink-microlattice-positioning` (whether BIONOVA X or Lumen X can fabricate flexible-electronics-compatible microlattices).

### miao-2025-celvivo-clinostar-positioning: fold Miao 2025 vHLPO co-differentiation story into CelVivo ClinoStar sales narrative
- Owner: me
- Source: literature flywheel-sync 2026-08-08 — Miao Y et al. (2025) Cell v2, DOI 10.1016/j.cell.2025.05.041, PMID 40592324, Wiki.js Id 1681, NocoDB row 93, SeaFile PDF https://fb.biokingdom.top/f/24704d54a95941449e2e/?dl=1. Deep-read synthesis at [`/sources/literature-miao-2025-cell-vascularization-v2-deepread.md`](/sources/literature-miao-2025-cell-vascularization-v2-deepread.md)
- Due: unscheduled
- Status: open
- Notes: **Strongest CelVivo ClinoStar product relevance rating (5) in any of the 3 new flywheel-sync papers** — the vHLPO single 3D EB co-induction (mesoderm+endoderm) protocol depends on 3D EB self-organization in low-shear rotating culture, which is exactly what ClinoStar provides. vHLPO 7% ECs vs traditional HLPO 0% is a clinically-meaningful differentiator that no competing 2D / static culture can match. Sales ammunition: "your lung organoid model is missing 100% of vasculature — ClinoStar co-differentiation gives you 7% ECs vs 0%". Cross-vendor co-marketing: CelVivo ClinoStar (culture) + Cellink BIO X (decellularized lung scaffold) + 3Brain HD-MEA (functional readout on the neural mesenchyme). Robin should fold this into the CelVivo industrial-customers program (existing `CelVivo_中国工业客户开发研究报告` v1 + v2 in vault) and pitch to pediatric-hospital pharma R&D accounts (FOXF1 ACDMPV rare disease).

### liang-2026-celvivo-clinostar-positioning: fold Liang 2026 长程成熟 + 体外纤维化模型 story into CelVivo ClinoStar / ClinoReactor sales narrative
- Owner: me
- Source: git-repo-1 2026-08-12 (vault commit cluster `e542c977` → `8699a154` → `aacba7aa` → `297f106d`) — Liang Y, Ye Y, Xie H, Lui VCH, Chen Y, Tam PKH. (2026) *Scientific Reports* DOI 10.1038/s41598-026-42990-2, PMID 41857098; Wiki.js Id 1716, NocoDB Id 770; SeaFile PDF https://fb.biokingdom.top/f/9d53cfaaa88a45b49b72/?dl=1 + 7 真图 (Fig1-7); vault path `04-Literature/Deep-Reads/Liver/2026-08-12_Liang_2026_SciRep_liver_organoid_fibrosis_platform.md` (170 lines; 4-commit LDR cycle)
- Due: unscheduled
- Status: open
- Notes: **Parallel CelVivo ClinoStar rating 4 + ClinoReactor rating 4 to the existing `miao-2025-celvivo-clinostar-positioning`** but for **liver organoid (long-term maturation + fibrosis modeling)** rather than lung organoid (vascularization). Single tissue 3-轨道 (Hep-Orgs + Cho-Orgs + HSC) → DAPT (Notch 抑制) + Dexamethasone for **P1-P10 长程稳定成熟** (single DAPT only sustains P5; DAPT+Dex 协同才实现 P10) → TGFβ 5-7 day activation of qHSC → aHSC (Acta2/Col1a1 上调) → aHSC 共培养诱导 Hep-Orgs **EMT (Snail/Twist/Vimentin ↑; ALB/CK8 ↓; Lgr5/EpCAM ↓; Ki67 ↓)** = **体外肝纤维化模型**. Sales ammunition: "你的肝类器官只能短期培养? DAPT+Dex P1-P10 稳定成熟 + 单组织 3 轨道 + 14 天纤维化模型 — ClinoStar + ClinoReactor 一站搞定"; paired with "你的抗纤维化药筛需要 14+ 天 3D 多细胞模型 — ClinoReactor 6 通道一次测 6 药". Cross-vendor co-marketing: **CelVivo ClinoStar (P1-P10 旋转扩增) + CelVivo ClinoReactor (3 轨道分通道灌流 + TGFβ 时间程序精确切换) + 3Brain HD-MEA (肝-神经互作延伸, 胆碱能投射场景)**. Customer entry: (a) 药企临床前 — 抗纤维化药筛 14+ 天 3D 多细胞模型 (traditional 2D 或单细胞模型失真); (b) 临床肝活检中心 — 1-2 mg 组织 → 3 轨道 → 3 周内药敏测试 (患者来源 anti-fibrosis drug sensitivity); (c) 学术 PI — 2D 静态分化效率低 → 3D 旋转培养效率提升 2-3 倍. Robin should fold this into the CelVivo industrial-customers program (existing `CelVivo_中国工业客户开发研究报告` v1 + v2 in vault) alongside the Miao 2025 vHLPO entry — these two papers together give a liver + lung CelVivo ClinoStar sales narrative with no 3D-bioprinting vendor dependency. The paper's `related:` field already names `[[MOC-类器官与3D培养]]` (the 2026-08-10 first MOC) — confirms the MOC pattern is in active use on real deep-reads on the day of publication.

### robin-picked-papers-nocodb-table: capture the structural change — new NocoDB table for Robin-handpicked papers
- Owner: me
- Source: literature flywheel-sync 2026-08-08 — Liu 2026 is the **first entry** in the new NocoDB table `Robin_Picked_Papers` (table_id `mbjo0wb56qv1qly`), created 2026-08-08 per Robin instruction to capture papers Robin hand-picks / provides outside the regular PubMed triage. The table is separate from the existing `Organoid_Literature` table.
- Due: unscheduled
- Status: open
- Notes: The new table has 9 fields: Title, DOI, Journal, Year, Authors, Source, wiki_url, pdf_url, deep_read_summary. Future handpicked papers should land in this table rather than in `Organoid_Literature` (which is PubMed-triage-driven). Verify with Robin: (a) what is the workflow for capturing a handpicked paper — manual PDF drop to `/home/ldw/.hermes/cache/documents/` and then trigger the LDR pipeline; (b) should the LDR pipeline auto-route by signal (PubMed triage vs handpicked), or does Robin always provide the routing signal.

### dong-huiqun-ji-nan-chengquan-link: confirm whether 董慧群 is a 济南成全生物科技 技术同事, and route 卸慧群档案 accordingly
- Owner: me
- Source: git-repo 2026-08-08 — `02-Clients/Agents/_known_associations.md` (commit `4b237a82`, Hermes Agent 2026-08-07 hook 4) maps 济南成全生物科技有限公司 (曹沛起) as the **only CelVivo ClinoStar-listed agent** in the 259-dealer China map (华北 + 山东 跨区重复登记). `02-Clients/Agents/董慧群.md` (2026-07-28 commit `21491578`) lists 董慧群 as CelVivo 产品技术同事 with `agency: 待补`.
- Due: unscheduled
- Status: open
- Notes: The 2026-08-07 hook 4 partial-resolution gave a likely candidate (济南成全生物科技 曹沛起 company) but the precise link to 董慧群 (and whether she is 济南成全的技术同事, or another dealer) is still unverified. Action: Robin to verify with 董慧群 directly via WeChat / 微信 (current open-question [`/open-questions.md`](/open-questions.md) `agent-dong-huiqun-celvivo`). Once confirmed: update `02-Clients/Agents/董慧群.md` frontmatter `agency` field, and update [`/sources/agents.md`](/sources/agents.md) "代理商品牌" column from "待补" to "济南成全生物科技 (曹沛起)". Until this is done, 董慧群's role in the 济南成全 book of business is unconfirmed.

### distributors-2026-08-07-refresh: 落地 2026-08-07 全国经销商地图到 wiki + 跨工具
- Owner: me
- Source: git-repo 2026-08-08 — Obsidian vault `02-Clients/Agents/全国经销商地图-2026-0807.md` + 7 区域分文件 (8-07 baseline, 259 dealers across 7 regions, net change -2 from 2026-07-24 baseline). Vault raw survives 2026-08-08 fetch as untracked files (commit `4b237a82` Lin Yongli "4 个经销商管理 Hook 升级").
- Due: unscheduled
- Status: open
- Notes: 8-07 baseline differs from 7-24 baseline in: (a) total 261 → 259 (华北 74 → 72); (b) 济南成全生物科技有限公司 (曹沛起) cross-region registration (华北 + 山东); (c) new `_known_associations.md` index maps CelVivo → 济南成全 / FemtoBiomed → 9X Bio → TriArm / 3Brain + Cellink → 0. Cross-reference: [`/sources/distributors-china-2026.md`](/sources/distributors-china-2026.md) has been updated to the 8-07 baseline + new associations table; [`/sources/agents.md`](/sources/agents.md) still needs the 董慧群 → 济南成全 link; [`/commitments.md`](/commitments.md) has follow-up for 成都百乐 vs 成都立德赛 decision (open-question `chengdu-baile-vs-lidesai-for-ou-xianhong`). End-customer coverage for 3Brain / Cellink / FemtoBiomed still 0 in the 259 baseline — see open-question `distributors-3brain-cellink-zero-coverage`.

### guo-2026-organoid-irb-checklist-rollout: commit IRB application checklist template + add Guo 2026 deep-read synthesis page + fold into CelVivo industrial-customers program
- Owner: me
- Source: git-repo-1 2026-08-17 — vault commit cluster `2e6f5989` → `00f824f2` → `a4fa5a32` (Guo Z & Zhang N 2026 Front Cell Dev Biol organoid IRB / ethics systematic review, Wiki.js ID 1724, NocoDB Id 3298, DOI 10.3389/fcell.2026.1721946) + new untracked `templates/类器官IRB申请清单.md` v1.0 (180 lines, Robin 8-16 实战沉淀, derived from the Guo 2026 paper)
- Due: unscheduled
- Status: open
- Notes: **First customer-facing template produced from a single deep-read** in Robin's vault — the IRB application checklist is the canonical "Robin 培训客户 IRB 申请" core material for class A tertiary hospitals running organoid IRB submissions. The 7 mandatory points + 5 customer Q&A + China vs International flow table + 10 attachments + 7 citations map directly to the CelVivo ClinoStar clinical-translation sales narrative (Guo 2026 lists CelVivo ClinoStar ⭐⭐⭐⭐ for IRB compliance ammunition). **Three follow-ups needed**: (a) **commit** `templates/类器官IRB申请清单.md` to `main` (currently untracked); (b) add a wiki-side deep-read synthesis page at `/sources/literature-guo-2026-front-cell-dev-biol-organoid-ethics-deepread.md` mirroring the pattern at `/sources/literature-liu-2026-nbme-shape-conformal-organoid-deepread.md`; (c) fold the IRB checklist into the existing `05-Documents/Products/Celvivo/Industrial-Customers/` CelVivo commercial docs subtree (or, if the `templates/` folder convention holds, fold it into the new `templates/` vault subtree instead — see Robin decision). Companion commitment to fold into Chinese customer IRB conversations: the checklist covers China《人类遗传资源管理条例》+ 《涉及人的生命科学和医学研究伦理审查办法》2023 — directly applicable to the next Class A tertiary hospital Robin visits for CelVivo or 3Brain training.

<!--
Structure for new entries:

### <topic-key>: <short title>
- Owner: me | team | other:<name> | unknown
- Source: <connector> — <short ref>
- Due: YYYY-MM-DD or unscheduled
- Status: open | waiting | blocked | done
- Notes: <optional context>

## By owner

### Mine
- (none)

### Team
- (none)

### Other
- (none)
-->

## Completed recently

<!--
Move done items here with a Completed: date so they stay auditable without cluttering Active.
-->